SK completed a $350m investment in the Center for Breakthrough Medicines.

SK, a holding company, completed a $350m investment in the Center for Breakthrough Medicines, an innovative cell and gene therapy focused contract development and manufacturing organization. "We chose to partner with SK based on our shared deep desire to cure cancer and eradicate genetic disease. Thousands of people are dying every day, and we have the ability to cure patients by manufacturing these new technologies. This unprecedented collaboration will allow us to bring over 700k square feet of capacity online, and hire 2k of the world's most brilliant, advanced therapy experts, all at the Discovery Labs site in King of Prussia, Pennsylvania," Brian O'Neill, Center for Breakthrough Medicines Chairman.